HRP20090417T1 - Combination treatment for multiple sclerosis - Google Patents
Combination treatment for multiple sclerosisInfo
- Publication number
- HRP20090417T1 HRP20090417T1 HR20090417T HRP20090417T HRP20090417T1 HR P20090417 T1 HRP20090417 T1 HR P20090417T1 HR 20090417 T HR20090417 T HR 20090417T HR P20090417 T HRP20090417 T HR P20090417T HR P20090417 T1 HRP20090417 T1 HR P20090417T1
- Authority
- HR
- Croatia
- Prior art keywords
- multiple sclerosis
- combination treatment
- cda
- alpha
- agent
- Prior art date
Links
- 238000011284 combination treatment Methods 0.000 title abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 abstract 3
- 102000006495 integrins Human genes 0.000 abstract 2
- 108010044426 integrins Proteins 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electrotherapy Devices (AREA)
- Transplanting Machines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63867404P | 2004-12-22 | 2004-12-22 | |
| EP04106910 | 2004-12-22 | ||
| PCT/EP2005/056943 WO2006067134A1 (fr) | 2004-12-22 | 2005-12-20 | Polytherapie contre la sclerose en plaques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090417T1 true HRP20090417T1 (en) | 2009-09-30 |
Family
ID=35789196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090417T HRP20090417T1 (en) | 2004-12-22 | 2009-07-27 | Combination treatment for multiple sclerosis |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20100129353A1 (fr) |
| EP (1) | EP1835922B1 (fr) |
| JP (1) | JP2008524310A (fr) |
| AT (1) | ATE431740T1 (fr) |
| AU (1) | AU2005318183B2 (fr) |
| CA (1) | CA2590471A1 (fr) |
| CY (1) | CY1109316T1 (fr) |
| DE (1) | DE602005014570D1 (fr) |
| DK (1) | DK1835922T3 (fr) |
| ES (1) | ES2325552T3 (fr) |
| HR (1) | HRP20090417T1 (fr) |
| IL (1) | IL183924A (fr) |
| NO (1) | NO20073635L (fr) |
| PL (1) | PL1835922T3 (fr) |
| PT (1) | PT1835922E (fr) |
| SI (1) | SI1835922T1 (fr) |
| WO (1) | WO2006067134A1 (fr) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2521565B1 (fr) * | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
| FR2534487B1 (fr) * | 1982-10-15 | 1988-06-10 | Dior Christian Parfums | Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede |
| US5310732A (en) * | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US5077211A (en) * | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| US6172197B1 (en) * | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9206318D0 (en) * | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6225447B1 (en) * | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| US5871907A (en) * | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| ES2136092T3 (es) * | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5885793A (en) * | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| US5872215A (en) * | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| US5208327A (en) * | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
| US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ATE199392T1 (de) * | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US6001809A (en) * | 1994-07-11 | 1999-12-14 | Elan Pharmaceuticals, Inc. | Inhibitors of leukocyte adhesion |
| GB9712818D0 (en) * | 1996-07-08 | 1997-08-20 | Cambridge Antibody Tech | Labelling and selection of specific binding molecules |
| US6194395B1 (en) * | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
| WO2003072040A2 (fr) * | 2002-02-25 | 2003-09-04 | Elan Pharmaceuticals, Inc. | Administration d'agents pour le traitement d'une inflammation |
| MXPA05010330A (es) * | 2003-03-28 | 2006-05-31 | Ivax Corp | Formulaciones de cladribina para el mejor suministro oral y a traves de la mucosa. |
-
2005
- 2005-12-20 AU AU2005318183A patent/AU2005318183B2/en not_active Ceased
- 2005-12-20 CA CA002590471A patent/CA2590471A1/fr not_active Abandoned
- 2005-12-20 PT PT05823965T patent/PT1835922E/pt unknown
- 2005-12-20 SI SI200530731T patent/SI1835922T1/sl unknown
- 2005-12-20 PL PL05823965T patent/PL1835922T3/pl unknown
- 2005-12-20 EP EP05823965A patent/EP1835922B1/fr active Active
- 2005-12-20 AT AT05823965T patent/ATE431740T1/de active
- 2005-12-20 DE DE602005014570T patent/DE602005014570D1/de active Active
- 2005-12-20 ES ES05823965T patent/ES2325552T3/es active Active
- 2005-12-20 US US11/722,487 patent/US20100129353A1/en not_active Abandoned
- 2005-12-20 JP JP2007547483A patent/JP2008524310A/ja not_active Withdrawn
- 2005-12-20 WO PCT/EP2005/056943 patent/WO2006067134A1/fr active Application Filing
- 2005-12-20 DK DK05823965T patent/DK1835922T3/da active
-
2007
- 2007-06-14 IL IL183924A patent/IL183924A/en not_active IP Right Cessation
- 2007-07-13 NO NO20073635A patent/NO20073635L/no not_active Application Discontinuation
-
2009
- 2009-07-27 HR HR20090417T patent/HRP20090417T1/xx unknown
- 2009-08-12 CY CY20091100869T patent/CY1109316T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005318183B2 (en) | 2011-03-31 |
| ATE431740T1 (de) | 2009-06-15 |
| DK1835922T3 (da) | 2009-08-03 |
| AU2005318183A1 (en) | 2006-06-29 |
| WO2006067134A1 (fr) | 2006-06-29 |
| ES2325552T3 (es) | 2009-09-08 |
| JP2008524310A (ja) | 2008-07-10 |
| IL183924A0 (en) | 2007-10-31 |
| DE602005014570D1 (fr) | 2009-07-02 |
| SI1835922T1 (sl) | 2009-10-31 |
| CY1109316T1 (el) | 2014-07-02 |
| US20100129353A1 (en) | 2010-05-27 |
| NO20073635L (no) | 2007-09-24 |
| EP1835922A1 (fr) | 2007-09-26 |
| CA2590471A1 (fr) | 2006-06-29 |
| PT1835922E (pt) | 2009-07-08 |
| PL1835922T3 (pl) | 2009-10-30 |
| EP1835922B1 (fr) | 2009-05-20 |
| IL183924A (en) | 2010-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05013642A (es) | Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer. | |
| GB2506085A (en) | Combination treatment (eg with ABT-072 or ABT-333) of DAAS for use in treating HCV | |
| UA101309C2 (ru) | Антагонисты активина-actrii и их применение для повышения уровня эритроцитов | |
| MXPA03010085A (es) | Composiciones y su uso en la hiperplasia. | |
| WO2007062093A3 (fr) | Polytherapie pour le traitement du cancer | |
| FR2869231B1 (fr) | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine | |
| EP3530288A3 (fr) | Procédés pour le traitement d'états pathologiques liés à l'activation du complément masp-2 dépendant | |
| BRPI0516531A (pt) | imunoterapia de distúrbios auto-imunes | |
| NO332893B1 (no) | Anvendelse av antistoff for fremstilling av medikament til anvendelse ved CVP-kjemoterapi | |
| HUP0002755A2 (hu) | Eljárások szklerózis multiplexben szenvedő betegek kezelésére konszenzus interferonnal | |
| SG160323A1 (en) | Methods for controlling angiogenesis and cell proliferation | |
| WO2004039325A3 (fr) | Compositions contenant un inhibiteur de jnk destinees a traiter, prevenir, gerer et/ou modifier la douleur, et leurs methodes d'utilisation | |
| DK1140198T3 (da) | Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad | |
| WO2003049694A3 (fr) | Methodes therapeutiques de traitement d'un lymphome non hodgkinien | |
| HK1112721A1 (en) | Tissue disruption treatment and composition for use thereof | |
| WO2005009363A3 (fr) | Traitements d'etats precancereux et prevention du cancer au moyen de therapies a base de pcdgf | |
| TW200420290A (en) | Methods for the treatment, prevention and management of macular degeneration | |
| JP2003528919A5 (fr) | ||
| HK1045456B (zh) | 病毒炎性調節蛋白在阻斷異種移植排斥中的治療新用途 | |
| DE602005014570D1 (fr) | ||
| TW200628162A (en) | Combination treatment for multiple sclerosis | |
| MXPA04005207A (es) | Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos. | |
| WO2003103675A3 (fr) | Polytherapies destinees aux troubles lies aux purinocepteurs | |
| WO2008060535A3 (fr) | Utilisation de la reversine et de ses analogues pour le traitement du cancer | |
| EP1374873B8 (fr) | Utilisation de la n-acetyl-d-glucosamine dans la preparation de compositions pharmaceutiques utilisees dans la suppression des effets secondaires causes par la radiotherapie et la chimiotherapie |